P3 Health Partners saw a revenue decline and reported a net loss in Q3 2025, impacted by unfavorable settlement adjustments. However, the company maintained stable underlying medical cost trends and continues to focus on operational efficiency and expansion of its Care Enablement Model.

P3 Health generated $355.8 million in revenue for Q2 2025, with medical margin reaching $30.6 million. The company continues executing its EBITDA improvement plan but reported a net loss of $43.7 million. Average at-risk membership decreased 9% YoY, though per-member funding improved.

P3 Health Partners posted a net loss of $20.48 million in Q1 2025, with revenues down 4% year-over-year. Medical margin and operating income both declined, affected by prior-year claims. The company affirmed its full-year guidance, citing progress in its turnaround strategy.

In Q4 2024, P3 Health saw revenue grow 7% year-over-year to $370.7 million, while net loss widened to $129.1 million. Medical margin decreased to $7.3 million, with a higher premium deficiency reserve impacting results. The company grew its at-risk membership to nearly 124,000.

P3 Health Partners reported a 26% year-over-year increase in revenue to $362.1 million. However, the quarter was impacted by lower risk adjustments, higher medical expenses, and retroactive adjustments, leading to a net loss of $102.9 million and the withdrawal of the company's previous fiscal year guidance.

P3 Health Partners reported a revenue increase of 15% compared to the prior year, driven by growth in capitated revenue. However, gross profit and medical margin decreased, leading to a net loss. The company is focusing on initiatives to enhance capabilities and achieve sustainable profitability.

P3 Health Partners reported a 29% year-over-year increase in total revenue, reaching $388.5 million in Q1 2024. The company's net loss was $49.6 million, an improvement compared to the previous year. They are reaffirming their 2024 guidance and anticipate reaching Adjusted EBITDA positive in 2024.

P3 Health Partners reported strong top-line results for 2023, with revenue of approximately $1.27 billion, representing 21% growth and exceeding the top end of the guidance range. The company reaffirms its 2024 outlook based on strong growth in membership, increased funding, and stabilized medical cost trends. P3 experienced higher medical expenses in December due primarily to increased hospital admissions with the combination of COVID-19 and flu exacerbations.

P3 Health Partners reported a 16% increase in total revenue to $288.4 million for the third quarter of 2023, with a net loss of $37.3 million. The company reaffirmed its full-year 2023 guidance and provided preliminary 2024 full-year Adjusted EBITDA guidance of $20 million to $40 million.

P3 Health Partners reported a 21.9% increase in capitated revenue, reaching $325.6 million, and a significant reduction in net loss to $27.6 million compared to the prior year. The company's adjusted EBITDA improved to $0.2 million, and gross profit increased to $26.8 million, reflecting the effectiveness of P3's model and increasing membership maturity.

P3 Health Partners reported a strong start to 2023 with a medical margin of $39.2 million or 13.1% of capitated revenue. The company increased its Adjusted EBITDA guidance as a result of the first quarter strength.

P3 Health Partners announced their Q4 2022 financial results, highlighting revenue growth and a network contribution improvement of 65% versus 2021. The company secured financing of approximately $90.0 million and anticipates reaching Adjusted EBITDA positive in early 2024.

P3 Health Partners reported a strong quarter of growth with a 75% revenue increase year-to-date compared to the prior year period. The company's healthcare model enables collaboration between payors, patients, and providers to improve patient outcomes.